Table 4.

Final Adjusted Model*† for the Likelihood of Antiviral Prescription

Sign/SymptomEstimate (β coefficient)aOR (95% CI)
PCR guided care†0.461.57 (1.09–2.28)
Myalgia1.303.65 (2.35–5.68)
Duration of symptoms (≤2 days Vs >2 days)1.775.89 (4.18–8.28)
Fever0.932.52 (1.57–4.05)
Tonsillar exudate−1.670.19 (0.05–0.77)
Unclear lungs1.052.86 (1.58–5.17)
Clinic 20.131.13 (0.75–1.72)
Clinic 30.742.09 (1.34–3.25)
Nasal discharge0.802.24 (1.19–4.19)
Chills0.872.38 (1.25–4.53)
Enlarged tonsils−0.710.49 (0.25–0.95)
Intercept−5.13————

  • ↵* Hosmer-Lemeshow χ2 statistic, 3.16; df = 10; P = .92; AUROCC, 0.86.

  • ↵† Unadjusted OR, 2.10 (1.57–2.82).

  • aOR, adjusted odds ratio; CI, confidential interval; PCR, polymerase chain reaction.